Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Waldron Medical Research & Development, LLC

Neither a doctor nor a teaching hospital

Research payments

$2,574,601

124 payments

Through program year 2025, Waldron Medical Research & Development, LLC is reported as receiving $2,574,601 in research payments, across 124 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $91,487 2
2024 Research $129,938 7
2023 Research $75,964 8
2022 Research $373,221 25
2021 Research $563,524 35
2020 Research $698,234 29
2019 Research $642,233 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,828,887 69 payments
  2. AstraZeneca UK Limited $446,722 8 payments
  3. Daiichi Sankyo Inc. $295,568 46 payments
  4. Celgene Corporation $3,424 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON $554,624 13 payments
  2. A Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER) $498,420 7 payments
  3. A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer $460,024 13 payments
  4. A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION $435,563 7 payments
  5. Ds8201-A-U302 $164,171 25 payments
  6. A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID 19 $84,177 1 payment
  7. Study name not reported $57,156 10 payments
  8. Ds8201-A-U302 $53,468 5 payments
  9. A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) $42,575 3 payments
  10. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $38,007 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record